Suppression of skin inflammation in keratinocytes and acute/chronic disease models by caffeic acid phenethyl ester
- Authors
- Lim, Kyung-Min; Bae, SeungJin; Koo, Jung Eun; Kim, Eun-Sun; Bae, Ok-Nam; Lee, Joo Young
- Issue Date
- Apr-2015
- Publisher
- Springer Verlag
- Keywords
- Caffeic acid phenethyl ester (CAPE); Skin inflammation; Nuclear factor kappa B (NF-kappa B); Atopic dermatitis; TPA-induced ear edema
- Citation
- Archives of Dermatological Research, v.307, no.3, pp 219 - 227
- Pages
- 9
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Archives of Dermatological Research
- Volume
- 307
- Number
- 3
- Start Page
- 219
- End Page
- 227
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/18759
- DOI
- 10.1007/s00403-014-1529-8
- ISSN
- 0340-3696
1432-069X
- Abstract
- Skin inflammation plays a central role in the pathophysiology and symptoms of diverse chronic skin diseases including atopic dermatitis (AD). In this study, we examined if caffeic acid phenethyl ester (CAPE), a skin-permeable bioactive compound from propolis, was protective against skin inflammation using in vitro cell system and in vivo animal disease models. CAPE suppressed TNF-alpha-induced NF-kappa B activation and expression of inflammatory cytokines in human keratinocytes (HaCaT). The potency and efficacy of CAPE were superior to those of a non-phenethyl derivative, caffeic acid. Consistently, topical treatment of CAPE (0.5 %) attenuated 12-O-tetradecanoylphorbol-13-acetate(TPA)-induced skin inflammation on mouse ear as CAPE reduced ear swelling and histologic inflammation scores. CAPE suppressed increased expression of pro-inflammatory molecules such as TNF-alpha, cyclooxygenase-2 and inducible NO synthase in TPA-stimulated skin. TPA-induced phosphorylation of I kappa B and ERK was blocked by CAPE suggesting that protective effects of CAPE on skin inflammation is attributed to inhibition of NF-kappa B activation. Most importantly, in an oxazolone-induced chronic dermatitis model, topical application of CAPE (0.5 and 1 %) was effective in alleviating AD-like symptoms such as increases of trans-epidermal water loss, skin thickening and serum IgE as well as histologic inflammation assessment. Collectively, our results propose CAPE as a promising candidate for a novel topical drug for skin inflammatory diseases.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/18759)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.